| 2015 | Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial | JOURNAL OF CLINICAL ONCOLOGY |
| 2023 | Long-term outcomes of dual vs single HER2-directed neoadjuvant therapy in NSABP B-41 | BREAST CANCER RESEARCH AND TREATMENT |
| 2018 | Molecular subtypes of colorectal cancer in pre-clinical models show differential response to targeted therapies: Treatment implications beyond KRAS mutations
| PLoS One |
| 2020 | Mouse-human co-clinical trials demonstrate superior anti-tumour effects of buparlisib (BKM120) and cetuximab combination in squamous cell carcinoma of head and neck
| BRITISH JOURNAL OF CANCER |
| 2015 | Nanomaterials for theranostics: Recent advances and future challenges | CHEMICAL REVIEWS |
| 2015 | Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial | LANCET ONCOLOGY |
| 2018 | Neopepsee: accurate genome-level prediction of neoantigens by harnessing sequence and amino acid immunogenicity information | ANNALS OF ONCOLOGY |
| 2020 | NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2+
| JOURNAL OF CLINICAL ONCOLOGY |
| 2020 | Peripheral natural killer cells and myeloid-derived suppressor cells correlate with anti-PD-1 responses in non-small cell lung cancer
| SCIENTIFIC REPORTS |
| 2015 | Phase II clinical and exploratory biomarker study of dacomitinib in patients with recurrent and/or metastatic squamous cell carcinoma of head and neck | CLINICAL CANCER RESEARCH |
| 2015 | Phase II clinical and exploratory biomarker study of dacomitinib in recurrent and/or metastatic esophageal squamous cell carcinoma
| ONCOTARGET |
| 2019 | PI3K/AKT/β-Catenin Signaling Regulates Vestigial-Like 1 Which Predicts Poor Prognosis and Enhances Malignant Phenotype in Gastric Cancer
| CANCERS |
| 2013 | Predicting Degree of Benefit From Adjuvant Trastuzumab in NSABP Trial B-31 | JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE |
| 2017 | Prognosis of stage III colorectal carcinomas with FOLFOX adjuvant chemotherapy can be predicted by molecular subtype
| ONCOTARGET |
| 2016 | Prognostic Tests for Estrogen Receptor-Positive Breast Cancer: Need for Global Consideration and Further Evolution | JAMA ONCOLOGY |
| 2015 | Prospective Validation of a 21-Gene Expression Assay in Breast Cancer
| NEW ENGLAND JOURNAL OF MEDICINE |
| 2018 | Selective Cytotoxicity of the NAMPT Inhibitor FK866 Toward Gastric Cancer Cells with Markers of the Epithelial-Mesenchymal Transition, Due to Loss of NAPRT | GASTROENTEROLOGY |
| 2019 | Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/NSABP B-31 Adjuvant Trial for Early-stage HER2-positive Breast Cancer | JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE |
| 2018 | Targeting mutant KRAS with CRISPR-Cas9 controls tumor growth
| GENOME RESEARCH |
| 2017 | The Effect on Surgical Complications of Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer: NRG Oncology/NSABP Protocol B-40 | ANNALS OF SURGICAL ONCOLOGY |
| 2018 | Tumour sidedness and intrinsic subtypes in patients with stage II/III colon cancer: analysis of NSABP C-07 (NRG Oncology) | BRITISH JOURNAL OF CANCER |
| 2019 | Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial | LANCET ONCOLOGY |
| 2020 | Validation of the NSABP/NRG Oncology 8-Gene Trastuzumab-benefit Signature in Alliance/NCCTG N9831
| JNCI CANCER SPECTRUM |
